(Alliance News) – Nuformix PLC celebrated receiving several patents on Monday, after grants in Europe and the United States signaled new protections for its fibrosis and oncology treatment technology.
Nuformix is a London-based company developing treatments for fibrosis and oncology through drug repurposing. Its shares were trading in London on Monday morning, up 12%, at 0.22 pence each.
The grants related to multiple patents held by Nuformix for NXP002, its lead asset and a potential new inhaled treatment for idiopathic pulmonary fibrosis.
On June 12, the European Patent Office officially granted patent number 3837238, which covers pharmaceutical forms of NXP002 under development as a potential new treatment for idiopathic pulmonary fibrosis.
Meanwhile, the US Patent & Trademark Office issued patent 17/365,490, which covers the use of patented dosage forms of Nuformix in the treatment of various diseases, including fibrotic lung diseases .
The US PTO also issued patent number 12012386, which represents the first patent issued for the second series of NXP004 cocrystals.
Nuformix’s NXP004 program is focused on developing novel, proprietary cocrystal forms of olaparib, a drug currently marketed by AstraZeneca PLC as Lynparza.
“I am delighted that we have received these multiple key patent grants for our NXP002 and NXP004 programs. The grant of the European patent represents the latest significant territory to confirm the protection of new drug forms enabling the development of NXP002 as a potential new treatment of the REIT,” said Executive Director Dan Gooding.
By Holly Beveridge, Alliance News reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All rights reserved.
